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Abstract: Inflammation is a central aspect of tumour biology and can contribute significantly to both
the origination and progression of tumours. The NFκB pathway is one of the most important signal
transduction pathways in inflammation and is, therefore, an excellent target for cancer therapy. In this
work, we examined the influence of four NFκB inhibitors—Cortisol, MLN4924, QNZ and TPCA1—on
proliferation, inflammation and sensitisation to apoptosis mediated by the death ligand FasL in the
HNSCC cell lines PCI1, PCI9, PCI13, PCI52 and SCC25 and in the human dermal keratinocyte cell
line HaCaT. We found that the selection of the inhibitor is critical to ensure that cells do not respond
by inducing counteracting activities in the context of cancer therapy, e.g., the extreme IL-8 induction
mediated by MLN4924 or FasL resistance mediated by Cortisol. However, TPCA1 was qualified
by this in vitro study as an excellent therapeutic mediator in HNSCC by four positive qualities:
(1) proliferation was inhibited at low µM-range concentrations; (2) TNFα-induced IL-8 secretion
was blocked; (3) HNSCC cells were sensitized to TNFα-induced cell death; and (4) FasL-mediated
apoptosis was not disrupted.
Keywords: HNSCC; NFκB; inhibitor; TPCA1; apoptosis; inflammation; TNFα; FasL
1. Introduction
Despite numerous innovations in cancer therapy, the successful treatment of tumours is still
a major medical challenge. Over the past few decades, it has become increasingly apparent that
there is no gold standard or single approach to therapy; every patient and every form of cancer must
be treated specifically. However, “central hallmarks” intrinsically characterize cancer, including (a)
autonomous proliferation, (b) tumour suppressor elimination, (c) migration/invasion activation and
subsequent metastasis, (d) angiogenesis, (e) replicative immortality, and (f) enhanced or complete
resistance to cell death [1]. Although the fate of cancer is closely linked to genes and their alleles,
physiological circumstances can contribute considerably. A key role is played by the immune system
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and/or inflammation, which itself can be the cause of the disease and can profoundly influence all of
the previously mentioned central hallmarks of cancer [2]. Thus, via treatment with anti-inflammatory
agents, both the incidence and mortality of different tumour types could be reduced [3,4]. Numerous
signal transduction pathways, e.g., RAS-RAF and MYC [5,6], are involved in pro-inflammatory and
tumour-promoting processes, however, the nuclear factor kappa light-chain enhancer of activated
B-cells (NFκB) pathway has a preeminent position in the context of cancer and inflammation.
The NFκB family of transcription factors consists of five members: NFκB1 (p50/p105), NFκB2
(p52/p100), c-Rel, RelA (p65) and RelB. The highly conserved Rel homology domain is common to all
and is responsible for DNA binding as well as for protein–protein interactions. In mammalian cells,
two primary signal transduction pathways play a pivotal role: the classical or canonical pathway and
the alternative or noncanonical pathway. The classical pathway is induced by cytokines such as tumour
necrosis factor (TNF)α or interleukin (IL)-1β, leading to the activation of the cytoplasmic classical
inhibitory κB (IκB) kinase complex (IKK), which comprises three subunits (IKK-α/β/γ). In the inactive
form, NFκB heterodimers are associated with IκB. In the classical pathway, IκBα is typically associated
with the p65/p50 heterodimer. The phosphorylation of IκBα by IKK leads to ubiquitination followed
by proteasomal degradation and thus to the release of p65/p50, which translocates into the cell nucleus
and regulates gene activity.
In contrast, the alternative pathway is mainly regulated by members of the TNF family, such
as lymphotoxin-β (LTβ), receptor activator of NFκB ligand (RANKL), B-cell activating factor (BAFF)
or CD40. In this pathway, ligand-mediated receptor activation leads primarily to the stabilisation of
NFκB-inducing kinase (NIK). NIK selectively activates IKKα, leading to phosphorylation of the NFκB
dimer p100/RelB. Proteolytic cleavage of p100 to p52 then allows the heterodimeric transcription factor
p52/RelB to translocate into the nucleus [7]. The classical and alternative pathways activate different
gene subsets. The classical pathway regulates the expression of genes encoding proteins responsible
for the innate immune response, such as cytokines (IL-1, IL-6, IL-8 and TNFα), chemokines (monocyte
chemoattractant protein 1 (MCP-1), IL-18 and CC-chemokine ligand 5 (CCL-5)), anti-apoptotic factors
(cellular FLICE-like inhibitory protein (cFLIP), inhibitor of apoptosis proteins (IAPs) and Survivin), cell
cycle regulators (cyclins) and adhesion molecules (ICAM-1, VCAM-1 and matrix metalloproteinases
(MMPs)) [8]. The alternative pathway is responsible for the regulation of adaptive immune response
genes and is involved in B-cell development and maturation, T-cell differentiation via the induction of
cytokines such as IL-12, and the development of secondary lymphoid organs [9–11].
These abovementioned genes play important roles in the development of cancer. Thus, NFκB
pathway inhibition is an excellent approach for cancer therapy. The relevance of this pathway in
tumour biology has been shown in different mouse models; for example, the deletion of IKK-β in
enterocytes decreased the tumour incidence in a colitis-associated colon cancer mouse model [12], and
overexpression of IκBα in liver cells in a hepatocarcinoma model blocked tumour development [13].
Moreover, the NFκB pathway was required for the development of tumours in a mouse model of lung
adenocarcinoma, and loss of p53 and expression of oncogenic KRAS resulted in NFκB activation [14].
The relevance of NFκB has also been shown in humans. Bortezomib (PS341), a dipeptide boronic acid,
inhibits the proteasome complex. Inhibition of NFκB through the accumulation of IκBs is thought to
play a key role in this process. Indeed, bortezomib is already approved for the treatment of multiple
myeloma [15,16]. Another example of the relevance of NFκB in human cancer is IKK inhibition by
aspirin. Aspirin blocked the initiation and progression of colorectal cancer [3,17].
Another key point is the known involvement of the NFκB pathway in resistance mechanisms
of cancer cells. On one hand, by the previously described intrinsic mechanisms, NFκB pathway
activation promotes cancer by creating an inflammatory milieu and inducing anti-apoptotic genes [18].
On the other hand, extrinsic activation or promotion of the NFκB pathway by chemotherapeutic agents
can facilitate resistance and thus counteract the therapy [19,20]. This phenomenon is thoroughly
demonstrated for the cytostatic agent cisplatin. NFκB activity is inversely correlating with cisplatin
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sensitivity in cancer cell lines. In addition, prolonged treatment with cisplatin may lead to cisplatin
resistance, which is correlated with increased activation of NFκB [21].
In head and neck squamous cell carcinoma (HNSCC), the NFκB pathway also plays an
important role through strong or constitutive pathway activation [22,23], which is accompanied
by high expression/release of inflammatory factors [23–26] and is partly responsible for tumour
progression [27]. HNSCC is one of the most common tumour entities, with over 600,000 new cases
diagnosed annually worldwide. The poor prognosis, with a 5-year survival rate of approximately 55%,
is striking [28]. In recent decades, the prognosis has not improved, despite intensive research and the
introduction of new adjuvant therapies [28,29]. Thus, developing new strategies for treating HNSCC
is imperative, and, for the abovementioned reasons, the NFκB pathway is an ideal target. In addition,
a variety of potential agents that intervene at various points in NFκB signal transduction have been
developed. The IKK complex in the classical NFκB pathway or NIK in the alternative pathway are
frequent targets [30].
In this work, we examined the influence of the four NFκB inhibitors Cortisol, MLN4924, QNZ
and TPCA1 on proliferation, inflammation and sensitisation to apoptosis mediated by the death ligand
FasL in the HNSCC cell lines PCI1, PCI9, PCI13, PCI52 and SCC25 [18] and in the human keratinocyte
cell line HaCaT.
2. Results
Since NFκB-mediated inflammation, as described above, is a major factor promoting tumour
formation as well as contributing to increased apoptosis resistance in tumours, the effect of four
mechanistically different NFκB inhibitors—Cortisol, MLN4924, QNZ and TPCA1—on the secretion of
inflammatory cytokines (IL-8 and TNFα), proliferation (relative cell number (RCN)) and sensitisation
to death ligand (FasL)-induced apoptosis was analysed in the HNSCC cell lines PCI1, PCI9, PCI13,
PCI52 and SCC25 as well as in the keratinocyte cell line HaCaT as the control/standard.
Cortisol belongs to the glucocorticoids and is often used to counteract inflammatory and
sometimes chronic processes, e.g., rheumatism or gout. Although its exact mechanism of action
is unknown, Cortisol leads to the inhibition of IκBα degradation and NFκB p65 phosphorylation and
thus to the suppression of NFκB target genes such as cyclooxygenase-2 (COX-2), TNFα, IL-1β, and
IL-6 [31]. MLN4924 represses the ubiquitin proteasome system by inhibiting neural precursor cell
expressed, developmentally downregulated 8 (NEDD8) activating enzyme (NAE) [32]. This molecule
acts as a potent inhibitor of NFκB activation by, e.g., inhibiting the degradation of IκBα, and the
reduced p100 processing leads to NIK accumulation [33,34]. MLN4924 suppresses the growth of and
radio sensitizes HNSCC cells and tumours [35]. QNZ shows strong inhibitory effects on both NFκB
transcriptional activation and TNFα production, although the mechanism is unknown. Furthermore,
QNZ exhibited an anti-inflammatory effect on carrageenan-induced paw oedema in rats [36]. TPCA1
is mainly an IKKβ inhibitor and, therefore, potently influences the classical pathway by inhibiting the
phosphorylation and degradation of IκBα by inhibiting the expression of NFκB target genes such as
COX-2, IL-6 and IL-8 [33,37].
2.1. HNSCC Cell Lines Secrete the Pro-Inflammatory Marker IL-8 and Are Responsive to TNFα
In HNSCC, the NFκB pathway is important because of its strong constitutive activation [22,23]
accompanied by robust initiation of inflammatory factor production [23–26], thus promoting tumour
progression [27]. In the first experiment, we analysed the pro-inflammatory status in our cell lines by
measuring the secretion of IL-8, a well-established marker of inflammation and NFκB pathway activity.
IL-8 secretion was found in the supernatant of all analysed cell lines after 24 and 48 h. Additionally, all
HNSCC cell lines were responsive to TNFα and exhibited a significant increase in IL-8 secretion after
24 and 48 h (Figure 1A). To exclude the possibility that TNFα-induced cell proliferation/cell death was
responsible for the difference in IL-8 secretion, the relative cell number was determined via crystal
violet staining. TNFα induced no or only a slight increase in cell proliferation (Figure 1B).
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Figure 1. Cells (2 × 104/well) were stimulated with or without TNFα (100 ng/mL) for 24 and 48 h. (A) 
IL-8 secretion was measured via ELISA of the supernatants. (B) Relative cell number (RCN) was 
measured via a crystal violet assay of the corresponding 96-well plate. RCN values were normalized 
to those of the 24 h control group (100%). Three independent experiments were performed to 
determine mean values and standard deviations (n = 3), which are presented above. Results were 
calculated by Wilcoxon rank-sum test. p < 0.05 indicates statistically significant IL-8 inducing effects 
of TNFα marked with *, highly significant p-values (<0.01) with ** and very highly significant p-values 
(<0.001) marked with ***. 
Figure 1. Cells (2 × 104/well) were stimulated with or without TNFα (100 ng/mL) for 24 and 48 h.
(A) IL-8 secr tion was measured via ELISA of the supernatants. (B) Relative cell number (RCN) was
measur d via a crystal violet assay of the corresponding 96-well plate. RCN alues were normalized to
those of the 24 h contro gr up (100%). T ree indepe ent experiments were performed to determ n
mean values and standard deviati ns (n = 3), which are pr s ted above. Resul calculated by
Wilcoxon rank-sum test. p < 0.05 indicates statistically significant IL-8 inducing effects f TNFα marked
with *, highly significant p-values (<0.01) with ** a very highly significa t p-values (<0.001) mark d
with ***.
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2.2. Inhibition of HNSCC Cell Proliferation by NFκB Inhibitors
In the next experiment, the effect of the four NFκB inhibitors on proliferation was investigated.
Figure 2 summarises the results for each individual inhibitor. The determined IC10 (10% inhibition with
respect to the relative cell number) and IC50 (50% of the maximum inhibition) values are summarised
in Table 1. Cortisol showed the weakest antiproliferative effect in all tested cell lines. At the highest
concentration (50 µg/mL), the relative cell number was only reduced to values between 62% and
91% of baseline (Table 2). In terms of the IC50, the next most potent inhibitor was TPCA1, with IC50
values between 5.3 and 24.2 µM. Notably, all cell lines were responsive to TPCA1, and the relative
cell numbers were reduced to values between 10.6% and 29.9% of baseline. QNZ was more effective
than Cortisol and TPCA1, with IC50 values between 1 and >10 µM, but only 3 of the 6 cell lines (PCI1,
PCI13, and HaCaT) responded with a reduction in the relative cell number of 50% or greater. In those
cell lines, the cell number was reduced to values between 5.7% and 96.3%. MLN4924 exhibited the
lowest IC50 values (between 0.8 and 17.4 µM); the relative cell number was reduced to values between
9.9% and 39.3%.
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Table 1. Cell line-specific IC10 and IC50 values for the NFκB inhibitors Cortisol, MLN4924, QNZ and
TPCA1. Cells (1 × 104/well) were stimulated for 72 h with the indicated concentrations of Cortisol,
MLN4924, QNZ and TPCA1. The RCN was determined via crystal violet staining and normalised to
that of the untreated control (100%). The IC10 and IC50 values were determined as described in the
material and methods section. Three independent experiments were carried out to determine mean
values (n = 3). Cell lines for which no IC10 or IC50 values could be determined are marked with *.
IC50 values of inhibitors showing no effect or only a minimal effect are marked with **. In these cases,
the maximum concentration is indicated. In PCI9 and PCI52, no IC10 could be determined for QNZ.
For cell lines marked with †, 1 µM was defined as the IC10 value.
Cortisol [µM] MLN4924 [µM] QNZ [µM] TPCA1 [µM]
IC10 IC50 IC10 IC50 IC10 IC50 IC10 IC50
PCI1 20 * >280 ** 0.2 1 0.05 1 4.6 9.7
PCI9 140 * >280 ** 3.1 * >4.8 * 1 † >10 ** 3.3 13.8
PCI13 140 * >280 ** 0.2 0.8 0.4 1.2 5.2 24.2
PCI52 140 * >280 ** 7.3* >17.4 * 1 † >10 ** 6.3 * >17 *
SCC25 140 * >280 ** 0.2 1.4 10 * >10 ** 3.5 6.1
HaCaT 140 * >280 ** 0.2 0.8 0.4 1.1 2 5.3
Table 2. Relative cell numbers (%) after 72 h of incubation with the highest concentrations of the
NFκB inhibitors. The table shows the RCN value after incubation for 72 h with Cortisol (50 µg/mL),
MLN4924 (100 µM), QNZ (10 µM) and TPCA1 (100 µM). The values agree with the values shown in
Figure 2 at the highest indicated concentration. The ± columns show the standard deviation.
PCI1 PCI9 PCI13 PCI52 SCC25 HaCaT
RCN ± RCN ± RCN ± RCN ± RCN ± RCN ±
Cortisol 62 6.6 75.5 8.8 71.3 2.8 86.9 0.7 91 2.3 72.6 4.6
MLN4924 9.9 4.2 39.3 4.6 4.4 1.9 35.6 4.1 15.0 2.5 18.5 5.5
QNZ 5.7 3.9 96.3 3.2 6.0 5.7 77.0 5.6 81.2 3.6 39.1 8.2
TPCA1 11.5 2.3 29.9 5.2 18.0 6.3 36.2 2.1 10.6 3.9 18.5 8.4
2.3. Inhibition of the Inflammatory Response in HNSCC Cells by NFκB Inhibitors
The aim of the next experiment was to analyse the potential of NFκB inhibitors to block
inflammation. Cells were incubated with the indicated concentrations of the respective inhibitors
with and without TNFα (5 ng/mL) for 48 h, and the amount of secreted IL-8 in the supernatant
was subsequently determined by ELISA. IL-8 is an established marker of both inflammation and
NFκB pathway activity [26,38]. The TNFα concentration of 5 ng/mL was chosen from earlier
evaluation experiments showing that this relatively low TNFα concentration is sufficient to stimulate
IL-8 production without overstimulating the NFκB pathway and thus abrogating the efficacy of the
inhibitors. The results are summarised in Figure 3. Cortisol had no significant effect on either basal
or TNFα-induced IL-8 secretion, and QNZ exhibited a similar pattern. While the basal level was
only slightly increased, TNFα-induced IL-8 secretion could not be inhibited. However, the results for
MLN4924 were pronounced. Although TNFα-induced IL-8 secretion was not significantly inhibited,
treatment with MLN4924 alone led to a massive increase in the basal IL-8 level in all HNSCC cell
lines. Compared to the other three NFκB inhibitors, TPCA1 exhibited a completely different effect. The
basal IL-8 level was lowered slightly; however, crucially, TNFα-induced IL-8 secretion was blocked,
remaining, at worst, at the basal level.
The HaCaT cell line should, in principle, serve as an internal standard, as it is a spontaneously
immortalised keratinocyte cell line and is thus similar to the phenotype of the HNSCC cell lines in
terms of the original squamous epithelium [39]. The effects of the NFκB inhibitors in this cell line were
nearly negligible. Although the IL-8 level increased after incubation with the inhibitor MLN4924, the
increase of 1.4-fold was significantly lower than that observed in the HNSCC cell lines.
Int. J. Mol. Sci. 2019, 20, 1306 8 of 20
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 19 
 
 
Figure 3. IL-8 secretion from HNSCC cell lines after incubation with the NFκB inhibitors Cortisol, 
MLN4924, QNZ and TPCA1 alone and in combination with TNFα. Cells (2 × 104/well) were 
preincubated for 6 h with the appropriate IC10 of each inhibitor and subsequently incubated for an 
additional 48 h with and without TNFα (5 ng/mL). IL-8 values were normalised to RCNs determined 
in a crystal violet assay of the corresponding 96-well plate, as described in the material and methods 
section. Representative results from a total of three independently reproduced experiments (n = 3) are 
presented. The Wilcoxon rank-sum test was used for statistical data evaluation. p < 0.05 depicts 
statistically significant IL-8 inducing or inhibiting effects of the indicated treatment by taking the 
corresponding cell proliferation into account marked by *. 
  
Figure 3. IL-8 secretion from HNSCC cell lines after incubation with the NFκB inhibitors Cortisol,
MLN4924, QNZ and TPCA1 alone and in combi ti ith TNFα. Cells (2 × 104/w ll) were
preincubated for 6 h with the appropriate IC10 f each inh bitor and ubseque tly incubated for an
additional 48 h with and without TNFα (5 ng/ L). IL-8 values were normalised to RCNs determined
in a crystal violet assay of the corresponding 96-well plate, as described in the material and methods
section. Representative results from a total of three independently reproduced experiments (n = 3)
are presented. The Wilcoxon rank-sum test was used for statistical data evaluation. p < 0.05 depicts
statistically significant IL-8 induci g or inhibiting effects of the indicated treatment by taking the
corresponding cell proliferation into account marked by *.
2.4. TNFα Induced HNSCC Cell Death after TPCA1 Stimulation
However, in HaCaT cells, combined stimulation with TNFα and TPCA1 led to a strong reduction
in the IL-8 level. In principle, TNFα can activate the classical NFκB pathway and thus influence
the expression of numerous genes, both pro-apoptotic and anti-apoptotic. Inhibition of the NFκB
pathway can lead to altered homeostasis of anti- and pro-apoptotic genes and render the inflammatory
factor TNFα, a death ligand, which triggers apoptosis [40–42]. The classical experiment involved
the incubation of cell lines (e.g., HaCaT) [43] with the antibiotic cycloheximide (CHX). CHX attacks
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ribosomes, inhibiting de novo protein synthesis and leading to cFLIP inhibition. TNFα consequently
induces apoptosis [44]. The same or a similar effect can be achieved by NFκB inhibitors. For example,
MLN4924 sensitizes monocytes and maturing dendritic cells to TNF-dependent and independent
necroptosis, another form of programmed cell death [45].
To determine whether the combination of TNFα and TPCA1 leads to a reduction in cell number,
all cell lines were stimulated with the cell line-specific IC10 of TPCA1 and 100 ng/mL TNFα for 72 h
(Figure 4). In principle, TPCA1 reduced the relative cell number in all cell lines, thus not only blocking
IL-8 secretion via the classical NFκB pathway but also allowing the induction of cell death via TNFα.
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Figure 4. Relative cell number after stimulation with NFκB inhibitor TPCA1 in combination with TNFα.
To determine whether the combination of TNFα and TPCA1 leads to a reduction in cell number via cell
death, all cell lines (1 × 104/well) were stimulated with TNFα (100 ng/mL) and the cell line-specific
IC10 of TPCA1 for 72 h and stained with crystal violet. Data of one representative experiment are
shown (n = 3). Results were analysed using the Wilcoxon rank-sum test. A significance level of p < 0.05
was established to indicate statistically significant effects and marked with *.
2.5. Analysis of Extrinsic FasL-Induced Apoptosis in Combination with NFκB Inhibitors in HNSCC Cells
In a final experiment, we investigated whether the NFκB inhibitors used in this study are suitable
for sensitising HNSCC cell lines to FasL-induced extrinsic apoptosis. Cell lines were stimulated with
the cell line-specific IC10 of the NFκB inhibitors (Table 1) and increasing concentrations of the death
ligand FasL. Previous studies from our group showed that the cell lines used in this study express the
Fas receptor and can be sensitized to FasL-mediated apoptosis by the SMAC mimetics Birinapant and
LCL161, e.g., [46,47].
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Detailed results for Cortisol are shown in Figure 5. An overview of all cell lines and inhibitors is
provided in Table 3, which shows an analysis of sensitisation to apoptosis as numerical values for the
enhancement (x times) and the interaction index (y) described by Tallarida [48].
In summary, combination therapy with NFκB inhibitors and FasL exhibited no significant effect
in most cases. However, importantly, in some cases, the combination inhibited or strongly negatively
affected FasL-induced apoptosis. This effect is exemplified for Cortisol in Figure 5. The cell lines PCI9,
PCI52 and SCC25, which are generally not responsive to FasL, showed no sensitisation to apoptosis
in combination with Cortisol. The two FasL-responsive cell lines PCI1 and PCI13 even showed a
significant deterioration in apoptotic efficiency. While the efficiency in PCI1 cells was reduced by 60%,
PCI13 cells showed newly gained FasL resistance. The values in Table 3 show that most of the cell
lines, regardless of the inhibitor used, showed no significant changes in FasL sensitivity. The only two
exceptions were QNZ in PCI13 cells, which led to a 2.3-fold improvement in efficiency, and MLN4924
in SCC25 cells, which led to a 5-fold improvement. These results contrast with the results in the control
cell line HaCaT. Basically, sensitisation to FasL-induced apoptosis by NFκB inhibitors is possible. Here,
with the exception of Cortisol, all the inhibitors used imparted a clear increase in the efficiency of
FasL-induced apoptosis in HaCaT cells, with increases of 2.4-fold for QNZ, 2.5-fold for TPCA1 and
3.9-fold for MLN4924.
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 IC50 FasL [ng/mL] 
Efficiency 
IC50 FasLmono/ 
IC50 FasLkombi) 
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Index (y) 
PCI1    
FasL 37.3 - - 
Cortisol [IC10] + FasL >88.8 ± 0.4 ± 2.4 *** 
MLN4924 [IC10] + FasL 33.6 1.1 1.1 *** 
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Figure 5. Combination of Cortisol and FasL in HNSCC cell lines. (A) HNSCC cell lines (1 × 104/well)
were incubated with the indicated concentrations of FasL in combination with the cell line-specific
onstant IC10 of Cortisol as indicated in Table 1. The RCN was analysed fter 72 h via crystal violet
staining, and values were normalised to that of the control (100%). These graphs show data of three
independently reproduced experiments with the mean values and standard deviations (n = 3). Student’s
t-test was used for the statistical evaluation of these results to show significant effects when comparing
both therapies. To compare treatment efficacies, Tallarida’s interaction index was determined as
indicated in the material and method section. (B) HaCaT c lls (1 × 104/well) were incubated with
the indicated concentrations of FasL in combination with IC10 concentration of MLN4924, QNZ and
TPCA1 as indicated in Table 1. The RCN was analysed after 72 h via crystal violet staining, and the
values were normalised to that of the control (100%). Three independent experiments were carried out
with triplicate cultures. These graphs show data of three independently reproduced experiments (n =
3) with the mean values and standard deviations.
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Table 3. Efficiency quotient and interaction index (y) of combination therapy with NFκB inhibitors
and the death ligand FasL. HNSCC cell lines (1 × 104/well) were incubated with the indicated
concentrations of FasL in combination with the cell line-specific constant IC10 of the indicated NFκB
inhibitor (n = 3) as shown in Table 1. The values of the IC50 FasLmono and IC50 FasLcombi, efficiency
quotient and interaction index were determined as described in the material and methods section. The
interaction index, as described by Tallarida, for determining synergistic effects is annotated as follows:
* = superadditive (synergistic, resp.), ** = additive, *** = antagonistic. Samples with pro-apoptotic
sensitisation of the cells are highlighted in bold. Cell lines for which no IC50 could be determined
due to FasL resistance (PCI9, PCI52 and SCC25) as well as cell lines that remained resistant (PCI9 and
PCI52) are marked with †. Furthermore, samples for which a complete IC50 saturation curve was not
formed for FasL are designated with ‡. Samples for which the additional application of NFκB pathway
inhibitors led to a decrease in the FasL effect are marked with ±.
IC50 FasL [ng/mL]
Efficiency
IC50 FasLmono/
IC50 FasLkombi)
Interaction
Index (y)
PCI1
FasL 37.3 - -
Cortisol [IC10] + FasL >88.8 ± 0.4 ± 2.4 ***
MLN4924 [IC10] + FasL 33.6 1.1 1.1 ***
QNZ [IC10] + FasL 44.3 ± 0.8 ± 1.2 ***
TPCA1 [IC10] + FasL 41.9 ± 0.9 ± 1.6 ***
PCI9
FasL - † - -
Cortisol [IC10] + FasL >200 † 1 1.5 ***
MLN4924 [IC10] + FasL >200 † 1 1.7 ***
QNZ [IC10] + FasL >200 † 1 1.1 ***
TPCA1 [IC10] + FasL >200 † 1 1.2 ***
PCI13
FasL 55.5 - -
Cortisol [IC10] + FasL >200 ± 0.3 ± 4.1 ***
MLN4924 [IC10] + FasL >71.9 ± 0.8 ± 1.6 ***
QNZ [IC10] + FasL 24.4 2.3 0.8 *
TPCA1 [IC10] + FasL >55.1 ± 1 1.2 ***
PCI52
FasL - † - -
Cortisol [IC10] + FasL >200 † 1 1.5 ***
MLN4924 [IC10] + FasL >200 † 1 1.4 ***
QNZ [IC10] + FasL >200 † 1 1.1 ***
TPCA1 [IC10] + FasL >200 † 1 1.4 ***
SCC25
FasL - † - -
Cortisol [IC10] + FasL >200 † 1 1.5 ***
MLN4924 [IC10] + FasL 39.7 5 0.3 *
QNZ [IC10] + FasL >200 † 1 2 ***
TPCA1 [IC10] + FasL >200 † 1 1.6 ***
HaCaT
FasL >68.7 ‡ - -
Cortisol [IC10] + FasL >59.1 1.2 1.4 ***
MLN4924 [IC10] + FasL 17.6 3.9 0.5 *
QNZ [IC10] + FasL 28.7 2.4 0.8 *
TPCA1 [IC10] + FasL 27.5 2.5 0.8 *
3. Discussion
Inflammation is a central aspect in tumour biology and can contribute significantly to both the
origin and progression of tumours. Although the importance of inflammation in the context of cancer
has long been known, this aspect has become increasingly important due to NFκB inhibitors. The NFκB
pathway is one of the most important signal transduction pathways in inflammation and is, therefore,
an excellent target for cancer therapy.
In the last three decades, no progress has been made in HNSCC treatment; thus, the prognosis
is usually poor, with a five-year survival rate of 55% [28,29]. Since HNSCC is also characterized by
massive inflammation and strong activation of the NFκB pathway, NFκB inhibitors seem particularly
useful for this disease. By selecting Cortisol, MLN4924, QNZ and TPCA1, we adopted four inhibitors
that attack different nodes within the NFκB signaling pathway. We sought to analyse the effectiveness
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of these inhibitors in suppressing inflammation, reducing proliferation, and sensitising to apoptosis
mediated by the death ligand FasL in five HNSCC cell lines.
Of the four inhibitors used in this study, only TPCA1 truly qualifies for clinical use in HNSCC.
While Cortisol had little effect in the proliferation assays, QNZ, MLN4924, and TPCA1 potently
inhibited cell proliferation, with IC50 values in the lower µM range. Although these concentrations
are still quite high for the use of these agents as purely antiproliferative drugs, the antiproliferative
effect can be considered as an additional positive effect. With regard to use as anti-inflammatory
therapeutic agents, neither Cortisol nor QNZ showed a significant effect on decreasing the IL-8 level.
Even more strikingly, the effect of MLN4924 on the HNSCC cells was counterproductive due to the
strong increase in IL-8 secretion. Thus, because of the aim to use NFκB inhibitors as a therapeutic
approach to reduce inflammation, MLN4924 has been disqualified for use in HNSCC treatment based
on our in vitro data. TPCA1, however, showed inhibition of TNFα-induced IL-8 secretion. TNFα is
often an essential tumour promoter through mediating the production of pro-inflammatory factors.
A quite surprising result was found in the attempt to enable FasL-mediated apoptosis via NFκB
inhibitors. Basically, the inhibitors showed almost no beneficial effects, except for QNZ, which led to a
2.3-fold improvement in efficiency in PCI13 cells, and MLN4924, which led to a 5-fold improvement in
SCC25 cells. The results for Cortisol are extremely important due to the observed increase in apoptosis
resistance, even in the two FasL-responsive cell lines, PCI1 and PCI13, which showed a significant
deterioration in apoptotic efficiency. The efficiency in PCI1 cells was reduced by 60%, and PCI13 cells
showed newly gained FasL resistance.
The finding that TPCA1 can facilitate TNFα-mediated apoptosis is completely new. Importantly, this
effect was observed in all of the studied cell lines. In HNSCC, TNFα can inhibit apoptosis by activating
the Akt serine/threonine kinase [49]. However, altered homeostasis of intracellular factors may render
TNFα pro-apoptotic. This dual Janus-like role of TNFα has long been known [50]; examples are the
CHX-induced degradation of the anti-apoptotic factor cFLIP [42] and the use of NFκB inhibitors in
multiple myeloma cells [45], which enables the activation of programmed cell death by TNFα.
In vivo studies in HNSCC have shown that nonsteroidal anti-inflammatory drugs are beneficial
for patient survival [51]. Among the four inhibitors—Cortisol, MLN4924, QNZ and TPCA1—only a
few data directly related to HNSCC have been published. Thus, Cortisol has no significant advantage
for use in HNSCC therapy [52,53]. MLN4924 has already been shown to increase apoptosis in HNSCC,
as demonstrated by the decrease in the level of cFLIP, which promotes TRAIL-induced apoptosis
in HNSCC cells [54]. Another group showed that MLN4924 induced significant replication and
inhibited HNSCC cell proliferation both in culture and in HNSCC xenografts in mice. Additionally,
MLN4924 sensitizes HNSCC cells to ionising radiation (IR) and enhances IR-induced suppression
of xenograft growth in mice [35]. Zhang et al. provided more detailed insight into the mechanism
of MLN4924-induced apoptosis, as follows. The expression levels of NAE1 and UBC12 were higher
in HNSCC tissues than in normal tissues, and inactivation of the neddylation pathway significantly
inhibited malignant phenotypes in HNSCC cells. Mechanistic studies revealed that MLN4924 induced
the accumulation of the CRL ligase substrate c-Myc, which transcriptionally activated the pro-apoptotic
protein Noxa and triggered apoptosis in HNSCC [55]. The finding that MLN4924 induces massive IL-8
secretion in HNSCC cells is new. The mechanism is unclear, but the use of this agent in cancer therapy
must be tested intensively, since IL-8 secretion will be extremely counterproductive—as shown in
HNSCC, IL-8 may contribute to tumour progression [26,56]. In an additional experiment, we tested
the hypothesis that MLN4924 can induce the secretion of soluble TNFα and by this way induce the
autocrine/paracrine secretion of IL-8. The analysis of the HNSCC cell lines after 24 and 48 h of
stimulation with MLN4924 showed no significant detectable TNFα signal (except positive standard
control) in stimulated and unstimulated probes (data not shown). We found no data in the literature
regarding QNZ and TPCA1 in the context of HNSCC.
How should the results of this in vitro study be evaluated in terms of their basic informative
value? We believe that the use of Cortisol and MLN4924 on the basis of the in vitro data is critical.
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Although Cortisol showed no relevant effect in most cases, the increase in apoptosis resistance in 2 of
the 5 tested HNSCC cell lines must be considered. Additionally, the increase in IL-8 secretion induced
by MLN4924 must be assessed very carefully. Especially compared with the control cell line HaCaT,
the HNSCC cell lines exhibited clearly different responses to the inhibitors. In HaCaT cells, NFκB
inhibitors resulted in a minimal increase in IL-8 secretion (a maximal increase of 1.4-fold). Moreover,
regarding FasL-induced apoptosis MLN4924, QNZ and TPCA1 resulted in a significant increase in
FasL responsiveness in HaCaT cells; thus, the NFκB inhibitors showed the precise expected effects.
Why Cortisol has such a drastic counteracting effect in HNSCC cannot be clearly explained.
As already mentioned, two studies have demonstrated the inefficacy of Cortisol in HNSCC for the
induction of apoptosis [53] as well as the inhibition of proliferation [52]. For MLN4924, we could not
find comparable results in the literature for the observed induction of IL-8 secretion. Certainly, further
studies are needed to elucidate the molecular mechanisms underlying these results to rule out the
use of Cortisol and MLN4924 or to limit their use only for specific patients. QNZ effectively inhibited
proliferation at low concentrations, but this finding was the only convincing result in favour of this
inhibitor. TPCA1, however, qualified as a suitable NFκB inhibitor in HNSCC in all experiments and all
cell lines by four positive qualities: (1) Proliferation was inhibited by low µM range concentrations of
TPCA1; (2) TNFα-induced IL-8 secretion was blocked by TPCA1; (3) HNSCC cells were sensitised to
TNFα-induced cell death by TPCA1; and (4) TPCA1 did not interfere with FasL-mediated apoptosis.
But why is TPCA1 so effective compared to the other NFκB inhibitors? Based on the current
state of knowledge, the effect can’t be explained by a detailed molecular mechanism. However,
TPCA1 attacks the IKK2 complex specifically, while the other inhibitors affect only indirectly the IκBα
phosphorylation and/or the NFκB pathway. We assume that in the analysed HNSCC cells TPCA1 is
the only inhibitor that efficiently inhibits the classical NFκB pathway—TPCA1 alone was able to inhibit
IL-8 secretion. The other drugs may affect the classical or alternative pathway, but not specifically. In
HNSCC cells, they are more responsible for an imbalance in NFκB-regulated gene expression and a
rather unspecific cellular response. Furthermore, the influence of other signal transduction pathways
is also important. Cortisol, in its active form, is a transcription factor that can activate many gene
products, the exact mechanism of QNZ is unknown, and MLN4924 also does not specifically interfere
via the proteasomal degradation. Thus, the main advantage of TPCA1 is its selectivity, which also
contributes to the fact that this drug has no effect on FasL-mediated apoptosis in HNSCC cell lines.
We propose that the in vitro data collected in this publication indicate that TPCA1 is suitable for
clinical use. Further in vivo studies are needed to demonstrate the efficacy of this inhibitor in HNSCC.
4. Materials and Methods
All inhibitors of the NFκB signaling pathway analysed in this study were commercially purchased.
MLN4924 (pevonedistat; Hycultec, Beutelsbach, Germany), QNZ (EVP4593) and TPCA1 (both Absource
Diagnostics, Munich, Germany) were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, Darmstadt,
Germany) to 10 mM stock solutions. Cortisol was obtained as a ready-to-use solution in methanol (1
mg/mL) (Sigma-Aldrich, Darmstadt, Germany). Stock solutions were stored at−20 ◦C. In preliminary
experiments, the toxicity of DMSO and methanol was determined. The maximum concentrations used in
the experiments for DMSO (<=1%) and for methanol (<=5%) showed no significant toxic effects (reduction
of the relative cell number) in the cell lines we used. Ligand preparation of Fc-FLAG-FasL and wild-type
TNFα-FLAG was performed as previously described [57].
4.1. Cell Culture
The HNSCC cell lines PCI1, PCI9, PCI13 and PCI52 were established at the Cancer Institute of
the University of Pittsburgh (USA) [58] and have already been used in several studies, particularly in
studies of the cytotoxicity of antineoplastic drugs [47,58–60]. Cell lines were cultured in Dulbecco’s
modified Eagle’s medium with low glucose (DMEM low; Thermo Fisher, Karlsruhe, Germany)
supplemented with 10% fetal calf serum (FCS; Thermo Fisher), 1% penicillin/streptomycin (P/S;
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100 U/mL penicillin and 100 µg/mL streptomycin; Thermo Fisher) and 5 mL glutamine (4 mM;
Biochrom, Berlin, Germany). SCC25 and HaCaT cells were purchased from the American Type Culture
Collection (ATCC). SCC25 cells were cultured in DMEM/F-12 supplemented with HEPES (Thermo
Fisher), 10% FCS, 1% P/S and 5 µL of hydrocortisone (400 ng/mL; Sigma-Aldrich). HaCaT cells were
cultured in DMEM supplemented with 10% FCS and 1% P/S (Thermo Fisher). Cells were cultured at
37 ◦C in a humidified atmosphere containing 5% CO2.
4.2. Crystal Violet Staining (CytoTox) Assay
Cells were seeded in triplicate in 100 µL of culture medium (1 × 104 cells/well) overnight.
The following day, cells were incubated with NFκB inhibitors at the indicated concentrations for
72 h. For staining, supernatants were removed, and cells were incubated with 50 µL/well crystal
violet solution (1% crystal violet in 20% methanol; Carl Roth, Karlsruhe, Germany) for 12 min and
subsequently washed five times with distilled water. The plates were dried for 24 h in the dark. For
quantification, 100 µL/well methanol was added and incubated for a 12 min until the crystal violet
was completely dissolved. Photometric absorbance was measured at 595 nm using a microplate reader
(Tecan, Crailsheim, Germany). For data analysis the experiments were repeated three times to calculate
mean values and standard deviations (n = 3). The results were normalised to the untreated control
(100%). Therefore, the relative cell number values determined via the crystal violet assay with the
stimulated probes (CVS) were normalised to those of the untreated control (CVC) ((CVS/CVC) =
CVR). To obtain percentage values, CVR was multiplied by 100 (RCN (%) = (CVS/CVC) × 100 =
CVR%). For statistical analysis, these results were evaluated with Student’s t-test in order to show
significant sensitising effects of the investigated NFκB inhibitors in combinational treatment with FasL.
The significance level was set to p < 0.05.
4.3. ELISA
The anti-inflammatory effect of the NFκB pathway inhibitors was tested by ELISA under
unstimulated or TNFα-stimulated conditions or under treatment with NFκB inhibitors alone at the
indicated concentrations. A total of 2 × 104 cells/well were seeded in 100 µL/well culture medium
in 96-well plates. The following day, the medium was removed, and the cells were pre-incubated
in medium containing Cortisol, MLN4924, QNZ or TPCA1 for 6 h. After pre-incubation, TNFα was
added. Secretion of IL-8 and TNFα was investigated with ligand-specific ELISA kits (BD Biosciences,
Heidelberg, Germany). After 24 and 48 h, supernatants were harvested from duplicate wells and stored
at −20 ◦C until ELISA was performed. ELISA was carried out in accordance with the manufacturer’s
protocol. Briefly, capture antibodies were coated on a clear, high-binding ELISA plate (Greiner Bio-One,
Frickenhausen, Germany) overnight at 4 ◦C. Supernatants were incubated on the plate for 2 h and, after
a wash procedure, treated with streptavidin-horseradish peroxidase-conjugated detection antibodies.
After five intensive washes, 100 µL/well enzyme substrate (a 2:1 mixture of solutions A and B of the
“substrate pack” (BD Biosciences)) was added, and the reaction was stopped with stop solution (2 N
H2SO4) after 10 to 30 min. The results were quantified at 405 nm with an ELISA plate reader (Tecan) and
normalised to the ligand standard curve in ng/mL by linear regression analysis. For standardisation,
cytokine concentrations were correlated with the relative cell number quantified by the crystal violet
assay. Therefore, the concentration value for each secreted cytokine determined via ELISA with the
stimulated probes (ELISAS) was normalised to the corresponding value determined in the control
ELISA (ELISAC) to obtain the relative expression level (ELISAS/ELISAC = ELISAR). To normalise
the cytokine expression values to the relative cell numbers, the quotient ELISAR/CVR = ER was
determined for each value. In this case, the results for the ELISA and the crystal violet assay were
determined from the same 96-well plate. For statistical analysis, three independently performed
experiments were reproduced (n = 3) and statistics were calculated by Wilcoxon rank-sum test. p < 0.05
indicates statistically significant effects marked with *, highly significant p-values (<0.01) with ** and
very highly significant p-values (<0.001) marked with ***.
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4.4. Statistical Analysis
Data collection and plotting were performed with Excel (Microsoft, Redmond, WA, USA) and
GraphPad Prism (version 6.04; GraphPad Software, San Diego, CA, USA) software. Statistical analysis
was accomplished with GraphPad Prism and MEDAS (Grund EDV-Systeme, Margetshöchheim,
Germany) software. For analysis of the NFκB pathway inhibitor sensitisation effects, the half maximal
inhibitory concentration (IC50) was determined by for each drug and cell line using GraphPad
Prism. The IC50 is defined as the concentration that reach half maximal activity. For the combination
treatments, the initial inhibitory concentration (IC10) was determined as the concentration that reduced
the relative cell count by 10%. If no IC10 could be determined, the lowest concentration with significant
cytotoxicity was defined as the IC10 value. Via Student’s t-test, we compared the effects of FasL
monotherapy with those of combination treatment with FasL and NFκB pathway inhibitors. Here,
p-values < 0.05 indicated statistically significant effects of the combination therapy. The quantitative
assessment was evaluated by the interaction index (y) described by Tallarida [36] to identify synergistic,
additive or antagonistic effects. ELISA results were analysed using the nonparametric Wilcoxon
matched pairs signed rank test. A significance level of p < 0.05 was established to indicate statistically
significant effects. ELISA results were analysed using the Wilcoxon rank-sum test. A significance
level of p < 0.05 was established to indicate statistically significant effects and marked with *, highly
significant p-values (<0.01) with ** and very highly significant p-values (<0.001) marked with ***.
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Abbreviations
BAFF B-cell activating factor
CCL-5 CC-chemokine ligand 5
cFLIP Cellular FLICE-like inhibitory protein
CHX Cycloheximide
COX-2 Cyclooxygenase-2
CV Crystal violet
HNSCC Head and neck squamous cell carcinoma
IAP Inhibitor of apoptosis protein
ICAM-1 Intercellular adhesion molecule 1
IKK IκB kinase
IκB Inhibitory κB
IR Ionising radiation
KRAS Kirsten rat sarcoma
LTβ Lymphotoxin-β
MCP-1 Monocyte chemoattractant protein 1
MMP Matrix metalloproteinases
NAE NEDD8 activating enzyme
NEDD8 Neural precursor cell expressed developmentally down-regulated 8
NFκB Nuclear factor kappa light-chain enhancer of activated B-cells
NIK NFκB-inducing kinase
TNFα Tumour necrosis factor α
RANKL Receptor activator of NFκB ligand
RCN Relative cell number
VCAM-1 Vascular cell adhesion protein 1
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